← Ticker index
RARE
Ticker
RARE
Congressional Trades
16
by 1 members
Ticker disclosure brief
Congressional disclosure records for RARE
A ticker-first view of recent disclosures, reported ranges, filing lags, party aggregates, federal awards, lobbying records, and source-linked receipts.
Latest receipt
Gilbert Cisneros
BUY · 2026-03-03
Largest range
$1K – $15K
Gilbert Cisneros
Longest observed gap
38d
Gilbert Cisneros
Highest 30d vs SPY
53.4%
Gilbert Cisneros
Purchase rows
16
100%
Sale rows
0
0%
Disclosed midpoint
$128K
range estimate
Unique Traders
1
members
Disclosure timing method
Observed filing gaps are not notice-date findings
The reporting deadline is the earlier of 30 days after notice or 45 days after the transaction. Public disclosure rows provide transaction and filing dates, but do not establish when a member received notice. PoliWealth therefore marks only transaction-to-filing gaps over 45 days as an apparent delay for review; 31–45 day gaps are not labeled late from transaction date alone.
Party Breakdown
Democrats16 · 100%
Republicans0 · 0%
Lobbying filings
all →- 2026-07-13$0ULTRAGENYX PHARMACEUTICAL INC.Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD) Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD) Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD)
- 2026-04-20$10KULTRAGENYX PHARMACEUTICALIssues related to drug development and market access.
- 2026-04-20$0ULTRAGENYX PHARMACEUTICALn/a termination report
- 2026-04-20$0ULTRAGENYX PHARMACEUTICAL INC.Issues relating to rare disease and patient access.
- 2026-04-17$440KULTRAGENYX PHARMACEUTICAL INC.Issues related to drug development, access and reimbursement for rare and ultra rare diseases. Issues related to drug development, access and reimbursement for rare and ultra rare diseases. Issues related to drug development, access and reimbursement for rare and ultra rare diseases.
- 2026-04-17$60KULTRAGENYX PHARMACEUTICAL INC.Issues relating to rare disease and patient access. H.R.1262/S. 932 - Give Kids a Chance Act of 2025. FY 2027 Appropriations.
- 2026-04-17$0ULTRAGENYX PHARMACEUTICALIssues related to drug development and market access.
- 2026-03-30$0ULTRAGENYX PHARMACEUTICAL INC.Issues relating to rare disease and patient access.
- 2026-01-16$130KULTRAGENYX PHARMACEUTICAL INC.Issues related to drug development, access and reimbursement for rare and ultra rare diseases. Issues related to drug development, access and reimbursement for rare and ultra rare diseases. Issues related to drug development, access and reimbursement for rare and ultra rare diseases.
- 2026-01-16$60KULTRAGENYX PHARMACEUTICAL INC.Issues relating to rare disease and patient access. H.R.1262/S. 932 - Give Kids a Chance Act of 2025.
Loading trade analytics…
All Disclosed Trades
Page 1 · 16 of 16 shown| Date | Member | Action | Amount | Observed Gap | Receipt |
|---|---|---|---|---|---|
| 2026-03-03 | DGilbert Cisneros | BUY | $1K – $15K | 36d | receipt → |
| 2026-03-03 | DGilbert Cisneros | BUY | $1K – $15K | 36d | receipt → |
| 2026-03-03 | DGilbert Cisneros | BUY | $1K – $15K | 35d | receipt → |
| 2026-03-03 | DGilbert Cisneros | BUY | $1K – $15K | 35d | receipt → |
| 2026-02-18 | DGilbert Cisneros | BUY | $1K – $15K | 20d | receipt → |
| 2026-02-18 | DGilbert Cisneros | BUY | $1K – $15K | 20d | receipt → |
| 2026-02-18 | DGilbert Cisneros | BUY | $1K – $15K | 19d | receipt → |
| 2026-02-18 | DGilbert Cisneros | BUY | $1K – $15K | 19d | receipt → |
| 2025-08-08 | DGilbert Cisneros | BUY | $1K – $15K | 38d | receipt → |
| 2025-08-08 | DGilbert Cisneros | BUY | $1K – $15K | 35d | receipt → |
| 2025-08-08 | DGilbert Cisneros | BUY | $1K – $15K | 35d | receipt → |
| 2025-07-15 | DGilbert Cisneros | BUY | $1K – $15K | 31d | receipt → |
| 2025-07-15 | DGilbert Cisneros | BUY | $1K – $15K | 30d | receipt → |
| 2025-07-15 | DGilbert Cisneros | BUY | $1K – $15K | 30d | receipt → |
| 2025-07-15 | DGilbert Cisneros | BUY | $1K – $15K | 29d | receipt → |
| 2025-07-15 | DGilbert Cisneros | BUY | $1K – $15K | 29d | receipt → |
“Observed gap” is the calendar distance from transaction date to filing date; only gaps over 45 days receive an apparent-delay marker.